Hardman & Co Research
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet
further
30-March-2020 / 15:05 GMT/BST
Hardman & Co Research: $52.5m US deal strengthens balance sheet further
Diurnal is a commercial-stage specialty pharmaceutical company focused on
diseases of the endocrine system. Its two lead products are targeting rare
conditions where medical need is currently unmet, with the aim of building a
long-term 'Adrenal Franchise'. Alkindi(R) is currently being rolled out
through key European markets and has been submitted to the FDA for approval,
with a PDUFA date set at 29 September 2020. Meanwhile, Diurnal has signed an
exclusive US commercial deal with Eton Pharmaceuticals, a specialty pharma
company focused on hospital and paediatric products. This, together with the
recent Placing, has strengthened the balance sheet.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/52-5m-us-deal-strengt
hens-balance-sheet-further/ [1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link.
To contact us: Contact:
Hardman & Co Martin Hall mh@hardmanandco.com
35 New Broad Street
London
EC2M 1NH
+44 20 7194 7632
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of companies,
sectors, industries and investment securities. Our analysts are highly
experienced in their sectors, and have often been highly rated by professional
investors for their knowledge. Our focus is to raise companies' profiles
across the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been commissioned by
the company which is the subject of the note; this is clearly stated in the
disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative
of Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843. Hardman
Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community,
market counterparties and sophisticated and high net worth investors as
defined in the rules of the regulatory bodies. It is not intended to be made
available to unsophisticated retail investors. Anyone who is unsure of their
categorisation should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security. Please read
the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1010495 30-March-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=a57586daef3c7b4ab65b83748def7fcd&application_id=1010495&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1010495&site_id=vwd&application_name=news
(END) Dow Jones Newswires
March 30, 2020 10:05 ET (14:05 GMT)
